Halozyme Therapeutics (HALO) Receivables - Net (2010 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Receivables - Net of $458.0 million for Q1 2026, up 50.35% year-over-year from $304.6 million in Q1 2025, and up 3.79% quarter-over-quarter from $441.3 million in Q4 2025.
Halozyme Therapeutics (HALO) Receivables - Net (2010 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Receivables - Net for 17 consecutive years, with $458.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net rose 50.35% year-over-year to $458.0 million; the TTM figure through Mar 2026 stood at $458.0 million (up 50.35% YoY), while the FY2025 annual figure was $441.3 million, up 43.06% from the prior year.
- Receivables - Net grew to $458.0 million in Q1 2026 per HALO's latest filing, from $441.3 million in the prior quarter.
- Across five years, Receivables - Net topped out at $458.0 million in Q1 2026 and bottomed at $113.8 million in Q1 2022.
- Historically, Receivables - Net has averaged $264.4 million across 5 years, with a median of $235.1 million in 2022.
- Annual changes were most pronounced in 2022 — Receivables - Net surged 107.49% — and 2024, when it slipped 12.86%.
- Halozyme Therapeutics' Receivables - Net stood at $187.0 million in 2022, then climbed by 25.27% to $234.2 million in 2023, then surged by 31.7% to $308.5 million in 2024, then surged by 43.06% to $441.3 million in 2025, then gained by 3.79% to $458.0 million in 2026.
- Business Quant data shows HALO's Receivables - Net at $458.0 million in Q1 2026, $441.3 million in Q4 2025, and $346.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 455.83 Mn |
| Jun 30, 2026 | 455.83 Mn |
| Mar 31, 2026 | 457.99 Mn |
| Mar 31, 2026 | 457.99 Mn |
| Dec 31, 2025 | 441.27 Mn |
| Dec 31, 2025 | 441.27 Mn |
| Sep 30, 2025 | 346.04 Mn |
| Sep 30, 2025 | 346.04 Mn |
| Jun 30, 2025 | 316.34 Mn |
| Jun 30, 2025 | 316.34 Mn |
| Mar 31, 2025 | 304.62 Mn |
| Mar 31, 2025 | 304.62 Mn |
| Dec 31, 2024 | 308.46 Mn |
| Dec 31, 2024 | 308.46 Mn |
| Sep 30, 2024 | 285.74 Mn |
| Sep 30, 2024 | 285.74 Mn |
| Jun 30, 2024 | 214.52 Mn |
| Jun 30, 2024 | 214.52 Mn |
| Mar 31, 2024 | 195.90 Mn |
| Mar 31, 2024 | 195.90 Mn |